Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: Evogene Ltd (EVGN) Report Updated: Nov 23, 2015 | Print This Page

Get more stock ratings by Louis Navellier

Evogene Ltd (EVGN)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Biotechnology
Competitors: AVXL, EGRX, ZIOP, NBIX

Stock Analysis

Rating: Monthly View

November December January February March April May June July August September October

Rating: Weekly View

This Week: D down no change
Last Week: D same upgrade
Two Weeks Ago: F up upgrade
service keys

Evogene Ltd© quotemedia

Company Profile

Evogene Ltd., a plant genomics company, engages in the development of enhanced plant traits through the use of plant genomics. It primarily focuses on the development of food crops, including corn, soybean, cotton, canola, rice, and wheat, as well as castor for the production of biofuel. The company’s technologies include ATHLETE for gene discovery; Gene2Product for enhancing trait efficacy and probability of successful development of biotechnology seed products; and EvoBreed for breeding enhancement. It holds granted or pending patents to approximately 3,000 novel genes. The company has collaboration agreements with Bayer CropScience; Biogemma; Centre de Cooperation Internationale en Recherche Agronomique pour le Development; DuPont; Monsanto Company; Rahan Meristem (1998) LTD; Rasi Seeds (P) Ltd.; Syngenta; Vilmorin; Viterra; and Zeraim Gedera for the development of various products and provision of plant enhancement solutions. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Recent News: Evogene Ltd